Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese

Breadcrumb

  1. Home
  2. Microbiota 15 - April 2022
  3. Commensal clostridiales strains mediate effective anti-cancer immune response against solid tumours
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Microbiota 15 - April 2022
  3. Commensal clostridiales strains mediate effective anti-cancer immune response against solid tumours
Gastroenterology

Commensal clostridiales strains mediate effective anti-cancer immune response against solid tumours

Cancer

COMMENTED ARTICLE - ADULTS’ SECTION

By Pr. Harry Sokol
Gastroenterology and Nutrition Department, Saint-Antoine Hospital, Paris, France

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • Mail

Sections

About this article

Created 22 April 2022
Updated 21 July 2022

Comments on the article by Montalban-Arques et al. Cell Host & Microbe 2021 [1]

Despite overall success, T-cell checkpoint inhibitors for cancer treatment (anticancer immunotherapy) are still only efficient in a minority of patients. Gut microbiota was recently found to critically modulate anti-cancer immunity and therapeutic response. In this article the authors identified Clostridiales members of the gut microbiota associated with a lower tumour burden in colorectal cancer (CRC) mouse models. Interestingly, these commensal species are also significantly reduced in CRC patients compared with healthy cont rols. Gastric gavage administration of a combination of four Clostridiales strains (CC4) in mice prevented and even successfully treated CRC as stand-alone therapy. This effect was dependent on intratumoral infiltration and activation of CD8+ T cells. Administration of a single strain of Roseburia intestinalis or Anaerostipes caccae was even more effective than CC4. In a direct comparison, the CC4 combination supplementation outperformed anti-PD-1 therapy in CRC and melanoma mouse models. These findings provide a strong preclinical basis for exploring gut bacteria as novel stand-alone therapy against solid tumours.

WHAT DO WE ALREADY KNOW ABOUT THIS SUBJECT?

Gut microbiota plays a major role in the development of the immune system and maintenance of immune homoeostasis. Gut microbiota influence the immune system both on a local and systemic level, maintaining a balanced immune response. In common with a wide range of diseases such as obesity, chronic inflammatory bowel disease, neuropsychiatric disorders, and colorectal cancer (CRC), disruption to the microbial balance (dysbiosis) is implicated.

CRC, as one of the most frequently diagnosed malignant diseases, remains the leading cause of cancer deaths worldwide related to lifestyle (diet, tobacco, alcohol) or obesity risk factors, which are all closely related to changes in the composition of healthy gut microbiota.

Gut microbiota is altered in CRC patients, with an increase in taxa such as Bacteroides or Fusobacterium [2] and a decrease in bacterial Clostridiales taxa compared to healthy individuals [3]. A majority of colorectal tumours have low immunogenicity and therefore do not respond to current T-cell activation immunotherapies. Anti-PD-1, anti-PD-L1 and/or anti-CTLA4 monoclonal antibodies are only effective in 4-5% of CRC tumours with a mismatch repair defect or high microsatellite instability [4]. Recent studies have shown how some members of the gut microbiota are able to modulate the efficacy of anti-cancer treatments [5, 6]. In this study, the authors evaluated whether a cocktail of four bacterial strains, specifically associated with a low tumour burden in an experimental CRC model, could trigger an effective anti-tumour immune response.

KEY POINTS

  • Clostridiales bacteria are associated with low tumour burden in colon cancer mouse models
  • Certain Clostridiales bacteria are less abundant in colorectal cancer patients
  • A combination of four Clostridiales strains has a potent anti-tumour effect via CD8+ T cells
  • Clostridiales treatment is effective in solid tumour mouse models independently of anti-PD-1 cancer immunotherapy
Image

WHAT ARE THE MAIN INSIGHTS FROM THIS STUDY?

Based on animal models, the authors observed that mice with a microbiota low in Clostridiales bacteria (Ruminococcaceae and Lachnospiraceae families) had increased susceptibility to CRC. Based on these analyses, the authors selected a combination of four Clostridiales species (CC4), i.e. Roseburia intestinalis, Eubacterium hallii (Anaerobutyricum hallii), Faecalibacterium prausnitzii and Anaerostipes caccae, whose abundance is decreased in CRC patients, to conduct additional studies on mouse models. CC4 administration had an effect on the mice microbiota, with an increase in species belonging to the Ruminococcaceae and Lachnospiraceae families.

In several solid cancer models, including for CRC, lung and breast cancer, CC4 administration slowed down tumour growth. This benefit was primarily lymphocyte-mediated as it disappeared in mice without mature lymphocytes (Rag2 KO mice). The main candidates are interferon-gamma producing cytotoxic CD8+ T cells, which massively infiltrate the tumour in animals receiving CC4. The protective effect was also observed individually with each of the bacterial strains tested in a CRC model, but with varying degrees of efficacy (Figure 1). The therapeutic effect was unrelated to butyrate producing-bacteria.

Finally, in the CRC model (MC-38), the CC4 cocktail had a superior effect to anti- PD-1 immunotherapy. Moreover, no additive effect was observed among mice having received immunotherapy and the four bacteria.

Image

CONSEQUENCES IN PRACTICE?

This study has shown that in addition to having an adjuvant role in the immunotherapy treatment of cancer, some microbiota bacteria exert their own anti-cancer effect in solid tumour mouse models. These results pave the way to the development of cancer treatments in man based on gut microbiota. These therapies could be used alone or in combination with other “conventional” anti-cancer treatments. However, the patient groups that would benefit most from this type of therapeutic approach are yet to be determined.

Conclusion

This study in mice showed that bacterial Clostridiales strains, which are significantly lower in colorectal cancer patients, are effective in stimulating an anti-cancer response to solid tumours. The mechanisms involve activation of CD8+ T cells and are independent of anti-PD-1 immunotherapy.

Sources

1 Montalban-Arques A, Katkeviciute E, Busenhart P, et al. Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. Cell Host Microbe 2021 ; 29 : 1573-88.e7.

2 Montalban- Arques A, Scharl M. Intestinal microbiota and colorectal carcinoma: Implications for pathogenesis, diagnosis, and therapy. EBioMedicine 2019 ; 48 : 648-55.

3 Reis SAD, da Conceição LL, Peluzio MDCG. Intestinal microbiota and colorectal cancer: changes in the intestinal microenvironment and their relation to the disease. J Med Microbiol 2019 ; 68 : 1391-407.

4 Kamatham S, Shahjehan F, Kasi, P.M. Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer: Current Status, Recent Advances, and Future Directions. Curr Colorectal Cancer Rep 2019 ; 15 : 112-21.

5 Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018 ; 359 : 97-103.

6 Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018 ; 359 : 91-7.

Tags
Clostridiales Cancer Gut microbiota

en_view en_sources

    Focus
    Microbiota 15 - April 2022
    • Overview
      • New perspectives in autism: the role of microbiota in social communication
      • Microbiota in Covid-19 pandemic
    • Commented article
      • Commensal clostridiales strains mediate effective anti-cancer immune response against solid tumours
      • Early-life formula feeding is associated with gut microbiota alterations and increased antibiotic resistance in infants
    • Congress review
      • Microbiome topics at GASTRO 2021
    • Press review
      • Gut Microbiota #15
      • Vaginal Microbiota #15
    • Expert opinion
      • The blue poop challenge a reliable method to evaluate gut transit?
    Created 22 April 2022
    Updated 21 July 2022

    About this article

    To know more about this topic.

    Main topic

    Cancer

    Content type

    Article
    Microbiota in Covid-19 pandemic
    Early-life formula feeding is associated with gut microbiota alterations and increased antibiotic resistance in infants
    Focus

    Microbiota 15 - April 2022

    Overview

    New perspectives in autism: the role of microbiota in social communication Microbiota in Covid-19 pandemic

    Commented article

    Commensal clostridiales strains mediate effective anti-cancer immune response against solid tumours Early-life formula feeding is associated with gut microbiota alterations and increased antibiotic resistance in infants

    Congress review

    Microbiome topics at GASTRO 2021

    Press review

    Gut Microbiota #15 Vaginal Microbiota #15

    Expert opinion

    The blue poop challenge a reliable method to evaluate gut transit?
    Gastroenterology
    23.01.2023

    Idiopathic urethritis in men: new infectious etiologies?

    Read the article

    Everything you need to know about Irritable Bowel Syndrome (IBS)

    Accrediting training, infographics, expert’s video, thematic folder, news… Biocodex Microbiota Institute pr...

    Find out more

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irritable Bo...

    Find out more
    13.01.2023

    Insomnia in seniors: a link with the gut microbiota

    Read the article

    Gut Microbiota #17

    By Pr. Satu PekkalaAcademy of Finland Research Fellow, Faculty of Sport and Health Sciences, University of ...

    Find out more

    Impact of beer and non alcoholic comsumption on the gut microbiota

    By Pr. Bernd SchnablDivision of Gastroenterology, San Diego Digestive Diseases Research Center (SDDRC), UC ...

    Find out more

    Gut Microbiota # 16

    By Pr. Satu PekkalaAcademy of Finland Research Fellow, Faculty of Sport and Health Sciences, University of ...

    Find out more

    Highlights from the UEGW

    By Dr. Lucas WautersGastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium

    Find out more
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian
    • Portuguese

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    23.01.2023

    Idiopathic urethritis in men: new infectious etiologies?

    Read the article

    Impact of beer and non alcoholic comsumption on the gut microbiota

    By Pr. Bernd SchnablDivision of Gastroenterology, San Diego Digestive Diseases Research Center (SDDRC), UC ...

    Find out more

    Skin Microbiota #17

    By Pr. Satu PekkalaAcademy of Finland Research Fellow, Faculty of Sport and Health Sciences, University of ...

    Find out more

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo